Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Sales and Divestitures (2016 - 2018)

Amicus Therapeutics (FOLD) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $353442.0 as the latest value for Q1 2018.

  • For the quarter ending Q1 2018, Gains from Sales and Divestitures rose 7420.04% year-over-year to $353442.0, compared with a TTM value of $353442.0 through Mar 2018, up 7420.04%, and an annual FY2017 reading of $318200.0, up 12.88% over the prior year.
  • Gains from Sales and Divestitures was $353442.0 for Q1 2018 at Amicus Therapeutics, up from $318200.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $353442.0 in Q1 2018 and bottomed at $4700.0 in Q1 2017.
  • Average Gains from Sales and Divestitures over 3 years is $224508.4, with a median of $210911.0 recorded in 2017.
  • The sharpest move saw Gains from Sales and Divestitures increased 5.83% in 2017, then soared 7420.04% in 2018.
  • Year by year, Gains from Sales and Divestitures stood at $281900.0 in 2016, then rose by 12.88% to $318200.0 in 2017, then grew by 11.08% to $353442.0 in 2018.
  • Business Quant data shows Gains from Sales and Divestitures for FOLD at $353442.0 in Q1 2018, $318200.0 in Q4 2017, and $210911.0 in Q3 2017.